<DOC>
	<DOCNO>NCT02530138</DOCNO>
	<brief_summary>Introduction : Currently , Nonalcoholic Fatty Liver Disease ( NAFLD ) common liver disease world . The approved treatment lifestyle modification weight loss ; however , evidence patient normal low body mass index ( BMI ) . The aim study evaluate efficacy symbiotic supplementation NAFLD patient normal low BMI . Methods analysis : In randomize , double-blind , placebo-controlled clinical trial protocol , 21 case 21 control individually match base age sex . This 42 patient NAFLD supplement twice daily 28 wk either synbiotic placebo capsule . Both group advise follow energy balance diet physical activity recommendation .</brief_summary>
	<brief_title>The Effect Synbiotics Supplement Lipid Profile , Liver Enzymes , Inflammatory Factors Hepatic Fibrosis Lean Normal Weight Patients With Nonalcoholic Fatty Liver</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Age 18 70 year Body Mass Index ( BMI ) 25 Serum alaninaminotransferase 1.5 fold upper limit normal range Sonographic finding compatible hepatic steatosis ( degree 2 ) Diabetes Taking kind antibiotic two week recruitment History alcohol consumption pregnancy lactation Professional athletes Other liver disease ( viral/etc ) Use drug calcium channel blocker , high dose synthetic estrogen , methotrexate , amiodarone , steroid , chloroquine , immunosuppressive drug , lipidlowering agent , metformin vitamin E A history Hypertension , Cardiovascular disease , Pulmonary disease , Renal disease &amp; Celiac disease ; Cirrhosis History Upper GI surgery / Prior surgical procedure jejunoileal jejunocolic bypass , gastroplasty Following program lose weight recent 3 mo A history hypothyroidism Cushing 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>